Fleur M Ferguson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9140147/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery, 2018, 17, 353-377. | 46.4 | 679 |
| 2 | Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. ELife, 2019, 8, . | 6.0 | 184 |
| 3 | Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell, 2020, 183, 1714-1731.e10. | 28.9 | 163 |
| 4 | Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature Communications, 2020, 11, 4687. | 12.8 | 129 |
| 5 | A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science, 2014, 346, 638-641. | 12.6 | 128 |
| 6 | Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain. Journal of Medicinal Chemistry, 2013, 56, 10183-10187. | 6.4 | 92 |
| 7 | Selective Mediator dependence of cell-type-specifying transcription. Nature Genetics, 2020, 52, 719-727. | 21.4 | 84 |
| 8 | Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology, 2020, 16, 635-643. | 8.0 | 84 |
| 9 | Molecular Basis of Histone Tail Recognition by Human TIP5 PHD Finger and Bromodomain of the Chromatin Remodeling Complex NoRC. Structure, 2015, 23, 80-92. | 3.3 | 59 |
| 10 | TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. Cancer Cell, 2021, 39, 1262-1278.e7. | 16.8 | 49 |
| 11 | Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chemical Biology, 2018, 13, 2438-2448. | 3.4 | 44 |
| 12 | Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chemical Biology, 2020, 27, 525-537.e6. | 5.2 | 36 |
| 13 | Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. European Journal of Medicinal Chemistry, 2021, 221, 113481. | 5.5 | 27 |
| 14 | Binding Hotspots of BAZ2B Bromodomain: Histone Interaction Revealed by Solution NMR Driven Docking. Biochemistry, 2014, 53, 6706-6716. | 2.5 | 23 |
| 15 | Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell Chemical Biology, 2019, 26, 804-817.e12. | 5.2 | 19 |
| 16 | Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chemical Biology, 2020, 27, 1229-1240.e4. | 5.2 | 19 |
| 17 | Discovery and Structure–Activity Relationship Study of (<i>Z</i>)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 4880-4895. | 6.4 | 17 |
| 18 | Synthesis and Structure–Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6 <i>H</i> -benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-6-one Scaffold. Journal of Medicinal Chemistry, 2020, 63, 7817-7826. | 6.4 | 16 |

FLEUR M FERGUSON

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Discovery of a Series of 5,11-Dihydro-6 <i>H</i> -benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 908-912. | 2.8 | 15 |
| 20 | Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. Proteomics, 2021, 21, e2000098. | 2.2 | 15 |
| 21 | Structure–Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 346-352. | 2.8 | 14 |
| 22 | Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy. Frontiers in Cellular Neuroscience, 2022, 16, 801179. | 3.7 | 14 |
| 23 | Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. ACS Medicinal Chemistry Letters, 2019, 10, 1443-1449. | 2.8 | 11 |
| 24 | Characterization of a highly selective inhibitor of the Aurora kinases. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4405-4408. | 2.2 | 10 |
| 25 | Targeted protein degradation: Emerging concepts and protein state-specific targeting principles. Current Opinion in Chemical Biology, 2022, 67, 102114. | 6.1 | 7 |
| 26 | Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1985-1993. | 2.2 | 5 |
| 27 | Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9. Current Research in Chemical Biology, 2021, 1, 100008. | 2.9 | 3 |
| 28 | Tuned out. Nature Chemical Biology, 2022, 18, 917-918. | 8.0 | 3 |
| 29 | Harnessing Antibody-Mimetic Selectivity for Activation-State-Specific Targeted Degradation of Endogenous K-Ras. ACS Central Science, 2021, 7, 222-224. | 11.3 | 2 |
| 30 | Assembling a Robust Workflow for Characterizing Endogenous E3 Ligase Substrates. Biochemistry, 2021, 60, 2365-2366. | 2.5 | 0 |